Chang David D
President and CEO at ALLO; EVP, R&D, Chief Medical Off. at Kite Pharma, Inc.
- Sold, on record
- $16.7M
- Dollars the filings state
- Form 4 sales
- 19
- Latest Mar 16, 2026
- Form 144 notices
- 3
- Proposed sales
- Companies
- 2
- Filed as an executive or holder
Companies
- ALLOAllogene Therapeutics, Inc.President and CEO
- Kite Pharma, Inc.EVP, R&D, Chief Medical Off.
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
- ALLO300,199 shares
- Kite Pharma, Inc.186,715 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale ALLOPlan not statedMar 15, 2022 2022
Sold 23,648 shares at $7.65 ($181k)
Chang David D, President and CEO
Sold 1% of holdings ($17.7M position)2.3M shares leftFiling
- 2 Form 144 notice ALLONoticeMar 14, 2024 +730 days
Filed to sell 53,393 shares ($231k)
Chang David D, Officer
No 10b5-1 planFiling
- 3 Form 144 notice ALLONoticeFeb 3, 2025 +326 days
Filed to sell 46,003 shares ($77k)
Chang David D, Officer
No 10b5-1 planFirst sale on recordFiling
- 4 Form 4 sale ALLONo planFeb 3, 2025 same day
Sold 46,003 shares at $1.68 ($77k)
Chang David D, President and CEO
No 10b5-1 planSold 0.9% of holdings ($9M position)5.3M shares leftFirst sale on recordFollows a Form 144Filing
- 5 Form 144 notice ALLONoticeMar 14, 2025 +39 days
Filed to sell 46,668 shares ($91k)
Chang David D, Officer
No 10b5-1 planFiling
- 6 Form 4 sale ALLONo planMar 14, 2025 same day
Sold 46,668 shares at $1.96 ($91k)
Chang David D, President and CEO
No 10b5-1 planSold 0.9% of holdings ($10.4M position)5.3M shares leftFollows a Form 144Filing
- 7 Form 4 sale ALLONo planFeb 2, 2026 +325 days
Sold 95,269 shares at $1.80 ($171k)
Chang David D, President and CEO
No 10b5-1 planSold 1.8% of holdings ($9.5M position)5.2M shares leftFiling
- 8 Form 4 sale ALLONo planMar 16, 2026 +42 days
Sold 47,763 shares at $2.47 ($118k)
Chang David D, President and CEO
No 10b5-1 planSold 0.9% of holdings ($12.8M position)5.2M shares left1x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (22)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Mar 16, 2026 | Mar 18, 2026 | ALLO | President and CEO | Form 4 sale | 47,763 | $118k | 0.9% | No plan | SEC |
| Feb 2, 2026 | Feb 4, 2026 | ALLO | President and CEO | Form 4 sale | 95,269 | $171k | 1.8% | No plan | SEC |
| Mar 14, 2025 | Mar 18, 2025 | ALLO | President and CEO | Form 4 sale | 46,668 | $91k | 0.9% | No plan | SEC |
| Mar 14, 2025 | Mar 14, 2025 | ALLO | Officer | Form 144 notice | 46,668 | $91k | Notice | SEC | |
| Feb 3, 2025 | Feb 5, 2025 | ALLO | President and CEO | Form 4 sale | 46,003 | $77k | 0.9% | No plan | SEC |
| Feb 3, 2025 | Feb 3, 2025 | ALLO | Officer | Form 144 notice | 46,003 | $77k | Notice | SEC | |
| Mar 14, 2024 | Mar 14, 2024 | ALLO | Officer | Form 144 notice | 53,393 | $231k | Notice | SEC | |
| Mar 15, 2022 | Mar 17, 2022 | ALLO | President and CEO | Form 4 sale | 23,648 | $181k | 1.0% | Plan not stated | SEC |
| Mar 15, 2021 | Mar 17, 2021 | ALLO | President and CEO | Form 4 sale | 20,513 | $791k | 0.9% | Plan not stated | SEC |
| Mar 16, 2020 | Mar 18, 2020 | ALLO | President and CEO | Form 4 sale | 20,335 | $393k | 0.9% | Plan not stated | SEC |
| Sep 25, 2017 | Sep 27, 2017 | Kite Pharma, Inc. | EVP, R&D, Chief Medical Off. | Form 4 sale | 7,927 | $1.4M | 12.1% | Plan not stated | SEC |
| May 1, 2017 | May 3, 2017 | Kite Pharma, Inc. | EVP, R&D, Chief Medical Off. | Form 4 sale | 20,000 | $1.6M | 28.5% | Unusual | SEC |
| Apr 3, 2017 | Apr 4, 2017 | Kite Pharma, Inc. | EVP, R&D, Chief Medical Off. | Form 4 sale | 20,000 | $1.6M | 28.5% | Unusual | SEC |
| Mar 1, 2017 | Mar 2, 2017 | Kite Pharma, Inc. | EVP, R&D, Chief Medical Off. | Form 4 sale | 60,000 | $4.7M | 54.5% | Unusual | SEC |
| Dec 20, 2016 | Dec 22, 2016 | Kite Pharma, Inc. | EVP, R&D, Chief Medical Off. | Form 4 sale | 1,788 | $91k | 6.6% | Plan not stated | SEC |
| Nov 10, 2015 | Nov 12, 2015 | Kite Pharma, Inc. | EVP, R&D, Chief Medical Off. | Form 4 sale | 30,800 | $2.5M | 81.7% | Unusual | SEC |
| Nov 2, 2015 | Nov 4, 2015 | Kite Pharma, Inc. | EVP, R&D, Chief Medical Off. | Form 4 sale | 7,700 | $547k | 52.7% | Unusual | SEC |
| Oct 1, 2015 | Oct 2, 2015 | Kite Pharma, Inc. | EVP, R&D, Chief Medical Off. | Form 4 sale | 7,700 | $424k | 52.7% | Unusual | SEC |
| Sep 8, 2015 | Sep 8, 2015 | Kite Pharma, Inc. | EVP, R&D, Chief Medical Off. | Form 4 sale | 7,700 | $424k | 52.7% | Unusual | SEC |
| Aug 3, 2015 | Aug 4, 2015 | Kite Pharma, Inc. | EVP, R&D, Chief Medical Off. | Form 4 sale | 7,700 | $555k | 56.2% | Unusual | SEC |
| Jul 1, 2015 | Jul 2, 2015 | Kite Pharma, Inc. | EVP, R&D, Chief Medical Off. | Form 4 sale | 7,700 | $477k | 56.2% | Unusual | SEC |
| Jun 15, 2015 | Jun 17, 2015 | Kite Pharma, Inc. | EVP, R&D, Chief Medical Off. | Form 4 sale | 7,700 | $439k | 56.2% | Unusual | SEC |